G-CSF联合自体骨髓间充质干细胞移植治疗急性脑梗死的临床研究

目的探讨G-CSF联合自体骨髓间充质干细胞移植治疗脑梗死的临床效果。方法将42例急性脑梗死患者，随机分为2组：治疗组20例。对照组22例。治疗组给予G-CSF联合骨髓间充质干细胞移植治疗，对照组常规药物治疗。分别于发病时、治疗后三个月评价患者影像学（头MRI弥散像及灌注成像）及神经功能（用美国国立卫生研究院神经功能缺损评分NHISS和BI）变化。结果治疗3个月后，NIHSS积分与BI积分治疗组为4．8±2．0与78．5±7．2，对照组7．2±2．4与56．1±6．3，治疗组均优于对照组（P〈0．01）。治疗组头MRI灌注量亦优于对照组。治疗组未见明显不良反应。结论G-CSF与MSC联合是一种安全有效的方法，其疗效也优于传统治疗。

The dinical effect of rhG-CSF combined transplantation of autologous bone marrow mesenchymal stem cells on acute cerebral infarction

Objective To investigate the clinical effect of rhG-CSF combined transplantation of autologous bone marrow mesenchymal stem cells on cerebral infarction. Methods 42 acute cerebral infarction patients were randomly divided into tow groups: Injection rhGCSF combined autologous bone marrow mesenchymal stem cells group(treatment group, n=20)and conventionality therapy group(control group, n=22).The efficacy was assessed by National Institutes of Health Stroke Scale(NIHSS), Barthel Index(BI)and diffusion-weighted imaging(DWI),perfusion-weighted imaging(PWI)at baseline and the 3rd month after treatment. Result The scores of NHISS and BI treatment group were 4.8±2.0 and 78.5±7.2 respectively. while were 7.2±2.4 and 56.1±6.3 in control group at the 3rd month after treatment. The difference were significant(P＜0.01).PWI in treatment group Was higher than that in control group. There was no significant side-effect in treatment group. Conclusion rHG-CSF combined autologous bone marrow mesenchymal stem cells is a safe, efficient treatment for acute cerebral infarction patients, which is a better way than conventionality therapy.